MacroGenics

MacroGenics, based in Rockville, Maryland, and listed as MGNX, is an antibody engineering company behind margetuximab and a series of bispecific and antibody-drug conjugate programmes. Its Fc-optimisation and DART bispecific platforms produced margetuximab, sold as Margenza and approved in 2020 for HER2-positive breast cancer, vobramitamab duocarmazine, a B7-H3 ADC paused after toxicity, and lorigerlimab, a PD-1 by CTLA-4 bispecific. OnCo links it to HER2-positive breast cancer and to the margetuximab drug record. Whether platform companies can turn engineering advantages into products that beat entrenched antibodies is the question its record poses. Margetuximab has its own page.